Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — H1 FY26 Earnings Presentation
23 slides from Caplin Point Laboratories's earnings presentation, November 2025
Slide 1: Earnings Presentation H1 FY26
EARNINGS PRESENTATION H1 FY26 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* November 2025 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple CSU Incorporates Caplin projects equaling Rs. 600 commencement of Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris operations Markets Injectable unit launching
Slide 3: Q2 FY26 Income Statement
Q2 FY26 Income Statement Revenue from Operations Gross Profit EBITDA 10.5% 10.0% 18.3% YoY YoY YoY 534 324 220 510 315 201 483 294 186 Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 FY26 EBIT PAT Earnings Per Share 19.2% 22.5% YoY YoY 201 160 20.32 20.10 151 185 169 131 17.22 Q2
Slide 4: Q2 FY26 Profit Margins
Q2 FY26 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 61.7% 38.9% 37.7% 60.9% 60.6% 36.8% Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 FY26 EBIT Margins (%) PAT Margins (%) 35.6% 28.3% 28.4% 34.6% 33.5% 26.0% Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 FY26 4
Slide 5: H1 FY26 Income Statement
H1 FY26 Income Statement Revenue from Operations Gross Profit EBITDA 10.8% 12.5% 18.1% YoY YoY YoY 1,044 639 420 568 942 356 H1 FY25 H1 FY26 H1 FY25 H1 FY26 H1 FY25 H1 FY26 EBIT PAT Profit Margins 19.4% 21.6% YoY YoY 60.3% 61.2% 386 311 256 38.3% 36.3% 32.9% 35.1% 323 26.1% 28.3% H1 FY25 H1 FY26 H1
Slide 6: H1 FY26 Cash and Cash Equivalents and other Key Metrics
H1 FY26 Cash and Cash Equivalents and other Key Metrics Cash and Cash Equivalents Capital Investment Lifecycle 1,334 Cash Flow from 1,180 Operation: ₹ 254 Cr 916 194 192 772 694 146 470 94 91 284 77 73 65 223 47 49 101 126 26 26 27 46 68 8 Free Cashflow: ₹ 160 Cr FY 14 FY 15 FY 16 FY 17 FY 18 FY 19
Slide 7: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Point Laboratories said: • Managing Director Consistency has been the cornerstone of Caplin’s journey. We are pleased to report another strong set o
Slide 8: Q2 FY26 Highlights (Emerging Markets)
Q2 FY26 Highlights (Emerging Markets) 01 02 03 03 04 05 Caplin’s dominant presence in Company has won tenders in Company has filed its own Mexico Update – Company has Chile Update – Company begins Latin America continues to drive Central American markets to the internally developed GLP-1 filed 35+ p
Slide 9: Q2 FY26 Highlights (US and Regulated markets)
Q2 FY26 Highlights (US and Regulated markets) 01 02 03 04 Company successfully completes EU Caplin Steriles Limited (CSL) continues Company currently sits on 42 ANDA CSL has acquired 4 ANDAs from 3rd GMP reaudit in October ‘25, with NIL consistent and profitable growth in H1 approvals with a further
Slide 10: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved). R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue Continuous capex investment of over Rs. 887 Cr over last 8 years towards 89 2 85 enhanced manufacturing and R&D capabilities, from internal acc
Slide 11: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY25 Operating Revenue (Emerging Markets) (Emerging Markets) 35% 18% 6% 75% 25% 20% 76% 45% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 12: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 12
Slide 13: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: Manufacturing Units: • CP I: Puducherry • Nuevos Eticos Neo Ethicals S.A. • CP IV: Gummidipoondi • CP X: Vishakhapatnam Guatemala •
Slide 14: Manufacturing and R&D Platform
Manufacturing and R&D Platform Location of Plants and Facilities Tamil Nadu, India 1. SIDCO, Kakkalur, Near Chennai 1 2 2. Gummidipoondi, Chennai 43 3. Thervoy SIPCOT, Chennai 5 4. Corporate Office, Chennai 5. Suthukeny, Puducherry 6. APIIC, Visakhapatnam CP I CP III Puducherry Chengalpattu Andhra P
Slide 15: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Suthukeny, Caplin Plant I Injectables and Dual Existing Markets Nearing Completion Q3 FY26 Puducherry Chamber Syringes. API Facility Visakhapatnam, Existing and Regulated General API Comple
Slide 16: Caplin Point’s Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 17: Experienced and Visionary Board of Directors (1/2)
Experienced and Visionary Board of Directors (1/2) Mr. C.C. Paarthipan Dr. Sridhar Ganesan Mr. Vivek Partheeban Mr. Ashok Partheeban Dr. KC John Chairman Managing Director Vice Chairman Vice Chairman Independent Director 30+ Years of 35+ Years experience 20+ years of experience 23+ Years experience
Slide 18: Experienced and Visionary Board of Directors (2/2)
Experienced and Visionary Board of Directors (2/2) Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Independent Director Independent Director Independent Director Independent Director Retired IAS Officer Ph.D in Ecology and Post Graduate degree 35+ years of experience an
Slide 19: Q2 FY26 Consolidated Income Statement
Q2 FY26 Consolidated Income Statement (Rs. in Cr) Q2 FY26 Q2 FY25 YoY (%) Q1 FY26 QoQ (%) H1 FY26 H1 FY25 YoY (%) Revenue from Operation 534.04 483.10 10.5% 510.22 4.7% 1,044.26 942.06 10.8% Other Income 30.37 20.77 46.2% 23.14 31.2% 53.51 39.33 36.1% Total Revenue 564.41 503.87 12.0% 533.36 5.8% 1,
Slide 20: Visit Our Real Time ESG Disclosure Platform
Visit Our Real Time ESG Disclosure Platform At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations. Map our ESG framework with 35+ different frameworks Download ESG data Access to ESG factsheet Click to access ESG Profil
Slide 21: ESG and CSR
ESG and CSR ESG Commitments CSR INR 8.49 Crores Community Development Amount spent on CSR in FY25 ✓ Caplin Group’s state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai INR 3.19 Crores Amount spent on CSR upto H1FY26 Recycled Waste ✓ 60.2 MT waste recycled in 2025 Environmental &
Slide 22: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 23: Mr G Venkatram Simran Malhotra / Akshay Hirani
Mr G Venkatram [email protected] Simran Malhotra / Akshay Hirani [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited – All Rights Reserved. “Caplin Point” and The C
Caplin Point Laboratories — H1 FY26 Earnings Presentation on 6ix